Vilon Peptide: Lys-Glu Dipeptide Bioregulator and Its Limited Evidence

Vilon is a synthetic dipeptide made of just two amino acids, lysine and glutamic acid, usually written as Lys-Glu or KE. It belongs to a family of "peptide bioregulators" developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, originally derived from thymus-tissue extracts and later synthesized as a short, defined sequence.

That origin matters, because it sets expectations. Vilon is not a Western-approved medicine with a prescribing label and large randomized trials. It is a research-grade compound with an interesting but mostly preclinical evidence base: rodent longevity and tumor experiments, lymphocyte and macrophage cell-culture work, and a theoretical gene-regulation mechanism. The marketing language around it ("anti-aging," "immune restoration," "epigenetic reprogramming") runs far ahead of what the published primary literature can actually support.

This guide is educational and not medical advice. Vilon is an investigational research compound, not an approved therapy. Nothing here is a protocol, a dose recommendation, or an endorsement of human use.

For broader context on this whole category, see what peptides are and the peptide half-life guide. Vilon is often discussed alongside other Khavinson and longevity peptides such as epitalon, MOTS-c, and thymosin alpha-1, so it helps to keep the evidence bar consistent across all of them.

Vilon At A Glance

How Vilon Is Proposed To Work

The mechanistic story behind Vilon is genuinely interesting, but it is important to separate the hypothesis from what has been demonstrated.

The central idea, advanced by Khavinson and colleagues, is that very short peptides (two to four amino acids) are small enough to pass through cell and nuclear membranes, reach DNA, and bind to specific promoter sequences. In their molecular-docking modeling work, the Lys-Glu peptide is assigned a preferred short DNA recognition motif, and the authors argue that such binding could nudge the transcription of particular genes. They frame these ultra-short peptides as a possible class of epigenetic regulators.

Downstream of that proposed DNA interaction, Vilon has been reported to change chromatin structure. In cultured lymphocytes from older donors, Vilon was described as causing "deheterochromatinization," meaning a partial unwinding of condensed, transcriptionally silent chromatin, along with reactivation of ribosomal genes. The interpretation is that aging tends to lock away parts of the genome in facultative heterochromatin, and that Vilon partially reopens some of those regions. Notably, the same work reported that Vilon did not decondense stable, structural (pericentromeric) heterochromatin, which is a reasonable safety-relevant detail.

At the immune-signaling level, Vilon has been studied for effects on inflammatory and proliferation pathways. In a monocyte/macrophage (THP-1) cell-culture study, Vilon showed only a small modulatory capacity on kinase signaling overall, but it did contribute to STAT1 phosphorylation and reduced monocyte adhesion to activated endothelial cells, which the authors read as a mild anti-inflammatory signal. The honest summary: real but modest in-vitro effects, through mechanisms that appear receptor-independent and are still being worked out.

If you want a deeper look at how cells maintain their energy and stress systems during aging, compounds like SS-31 (elamipretide) and FOXO4-DRI target very different pathways and make a useful contrast to the gene-expression framing used for Vilon.

What The Evidence Actually Shows

Here is where careful reading matters. The Vilon literature is real and peer-reviewed, but it is dominated by animal and cell-culture work from a small group of investigators, with limited independent replication and essentially no large, controlled human trials.

The most cited longevity findings are in mice. In a 2000 report, the synthetic dipeptide Vilon was described as inhibiting the growth of spontaneous tumors and increasing life span in mice. A larger 2001 study in female CBA mice compared saline against the thymic dipeptide (Lys-Glu) and a pineal tetrapeptide given in short monthly courses, and reported effects on biomarkers of aging, survival, and spontaneous tumor incidence. Review summaries from the same group describe roughly 20-40% increases in mean (not maximum) life span across several of these peptide preparations.

Those are meaningful preclinical signals, but they come with caveats:

• They are rodent studies, often in specific inbred strains, and may not translate to humans.
• They come predominantly from one research program, which raises the value of independent replication.
• Mean life-span extension with reduced tumor burden can reflect general health or immune effects rather than a specific "anti-aging" gene mechanism.

The cell-culture data (chromatin reactivation in elderly-donor lymphocytes, modest THP-1 macrophage signaling, reported changes in markers like collagen and sirtuins in skin fibroblasts) are consistent with a tissue-level biological effect, but in-vitro changes are not clinical outcomes. None of this establishes that Vilon prevents disease, slows human aging, or "restores" the immune system in any measurable, durable way.

The bottom line on evidence: promising mechanism, suggestive rodent data, thin-to-absent human trial data.

Safety, Dosing, And What Is Unknown

Because Vilon is research-only, the most important safety fact is the absence of data, not a list of confirmed harms. There is no Western prescribing label, no established human pharmacokinetics, and no large safety database to draw from.

On dosing specifically: the original preparations in the Russian gerontology literature were typically given as short intramuscular injection courses, and animal experiments used small (microgram-to-milligram range) parenteral doses on intermittent schedules. These are experimental conditions, not human dosing guidance, and PeptideStat does not provide a recommended Vilon protocol because no validated one exists.

How To Evaluate A Vilon Claim

Vilon is a good test case for reading peptide marketing critically. When you see a strong claim, ask:

First, what is the evidence type? A mouse tumor study and a cell-culture chromatin assay are not the same as a human randomized trial. Most Vilon claims quietly rest on the former while implying the latter.

Second, how many independent groups have shown it? Much of the Vilon record traces back to a single research program. Independent replication is what turns an interesting hypothesis into established science.

Third, is "mean life span in mice" being upgraded into "anti-aging in humans"? That leap is not justified by the data.

Fourth, does the source acknowledge that Vilon is unapproved and unvalidated for human use? If a seller skips that, treat everything else they say with suspicion.

Fifth, is the proposed mechanism (DNA binding, chromatin remodeling) being presented as proven rather than as a model-based hypothesis? Mechanistic plausibility is not the same as clinical benefit.

This is the same lens you should apply to other longevity and brain peptides such as cerebrolysin: plausible biology, real but limited data, and marketing that outruns the evidence.

Bottom Line

Vilon (Lys-Glu) is a real, peer-reviewed research peptide with a coherent mechanistic story and some genuinely interesting preclinical findings, including reduced spontaneous tumor incidence and modest mean life-span extension in mice, chromatin reactivation in elderly-donor lymphocytes, and mild anti-inflammatory signaling in macrophage cultures.

But it remains exactly that: a research compound. It is not FDA-approved, has no recognized human indication, no validated dose, no robust human safety data, and limited independent replication. The popular framing of Vilon as a proven "anti-aging" or "immune-restoring" therapy is not supported by the primary literature.

Treat Vilon as investigational. If you are researching it, weight the rodent and cell-culture studies appropriately, distrust confident human claims, and recognize that the most accurate statement about Vilon in 2026 is that its promise is still unproven in people.

References

1. Khavinson VKh, Anisimov VN. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci. 2000;372:261-263.

2. Anisimov VN, Khavinson VK, Mikhalski AI, Yashin AI. Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mech Ageing Dev. 2001.

3. Lezhava T, Khavinson V, Monaselidze J, et al. Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. Biogerontology. 2004;5(2):73-79.

4. Avolio F, Martinotti S, Khavinson VKh, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022.

5. Khavinson VKh, Lin'kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016;162(2):288-292.

6. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149.

7. Anisimov VN, Khavinson VK, Morozov VG. Carcinogenesis and aging IV: effect of low-molecular-weight thymus, pineal and hypothalamus factors on immunity, tumor incidence and life span. Mech Ageing Dev. 1982.

8. Fan H, et al. Peptides as epigenetic modulators: therapeutic implications. Clin Epigenetics (review).